Objective: Hypoadiponectinemia has been proved to be closely related to endothelial dysfunction in peripheral arteries and is thought to be an independent risk factor for cardiovascular disease. The objective of this study was to investigate whether adiponectin might independently improve endothelial dysfunction in aorta isolated from high-fat-diet-induced obese. SpragueDawley rat and to study the mechanism involved. Research Design and Subjects: Male Sprague-Dawley rats were fed with a regular or a high-fat diet for 6 weeks. The aorta was isolated, and vascular segments were incubated with vehicle or the globular adiponectin (globular domain (gAD); 2 mg ml À1 ) for 2 h. The effect of gAD on endothelial function and nitric oxide (NO) production was determined. Human aortic endothelial cells in primary culture were treated with vehicle or gAD (4 mg ml À1 ). The effect of gAD on the level of phosphorylation of endothelial nitric oxide synthase (eNOS) at Ser1177, AMPK at Thr176 and Akt at Ser473 in endothelial cells were determined. Results: Severe endothelial dysfunction was observed in high-fat diet fed rat aortic segments. After gAd incubation, the endothelium-dependent relaxation was partly improved and total production of nitric oxide as result of enhanced eNOS activity was also increased. In the cultured endothelial cell line HUVEC, globular adiponectin increased the activity of eNOS through activating AMPK by stimulating its phosphorylation at Thr176 but not Akt.
Introduction
A lot of evidences suggest endothelial dysfunction, an early pivotal event in the development, progression and manifestation of macroangiopathy, 1,2 is closely correlated with obesity 3, 4 and plays a critical role in the development and onset of cardiovascular disease. 5 Numerous mechanisms have been proposed to explain this pathological alteration, 6, 7, 8 such as alteration of signaling mechanisms, alterations of nitric oxide synthase (NOS) expression and activity, and increased destruction of nitric oxide (NO) by superoxide, but the cross-talk between adipose tissue and endothelial dysfunction is still not quite clear.
Adiponectin is a novel cytokine secreted from adipose tissue. It contains a stalk with 22 collagen repeats and a highly conserved globular domain (gAD). In addition to its important role in metabolic process, adiponectin is involved in maintaining normal function of blood vessel and protects it against functional and structural disorders such as endothelial dysfunction, atherosclerosis and subsequent cardiovascular disease. Clinical observations have demonstrated that hypoadiponectinemia is closely related to endothelial dysfunction in peripheral arteries 9, 10 and that plasma total adiponectin concentrations are inversely related to the risk of cardiovascular disease. 11, 12, 13 It is logical to deduce that the obesity-related downregulation of adiponectin may be the critical link to obesity-associated endothelial dysfunction. Therefore, the aims of the present study were to determine whether globular adiponectin might independently improve endothelial function in vascular segments isolated from high-fat-diet-induced obese rat and, if so, to investigate the mechanisms involved.
Materials and methods

Reagents
Globular adiponectin was purchased from Aldipobiotech (Beijing, China). Norepinephrines (NE), acetylcholine (Ach), sodium nitroprusside (SNP), nitro-L-arginine methyl ester (L-NAME) and Compound C were obtained from SigmaAldrich (St Louis, MO, USA). Anti-phospho-eNOS (Ser1177), anti-phospho-AMPK (Thr172) and anti-phospho-Akt (Ser473) were obtained from Cell Signaling Technology (Beverly, MA, USA).
Experimental animal
All experimental animals were housed and used according to the guidelines of the Belgian Regulations for Animal Care, and were approved by the local authorities for animal research. Male Sprague-Dawley rats 2-3 weeks of age and weighing between 85 and 108 g were randomized to receive a regular chow diet (control group) or a high-fat (fat 20%, glucose 10%, dry powder of yolk 10%, standard chow 60%, 492.8 kcal 100 g À1 )-supplemented diet (obese group). Food and water were provided ad libitum and animals were maintained in a temperature-controlled barrier facility with a 12:12-h light-dark cycle. Body weight was monitored weekly. At the end of six weeks animals were sacrificed by pneumothorax. The visceral fat (VF, including epididymal fat, perirenal fat, mesenteric fat) were harvested and weighed. Thoracic aortas were dissected free and placed in ice-cold Krebs-Henseleit buffer continuously gassed with a mixture of 95% oxygen and 5% carbon dioxide, and containing the following (mM): NaCl (118.3), KCl (4.7), KH 2 PO 4 (1.2), MgSO 4 (1.2), NaHCO 3 (25.0), CaCl 2 (2.5) and dextrose (5.5). Aorta from each rat was divided into four rings of 3-mm length.
Aortic rings incubation
Each of the aortic rings was incubated in a cell-culture incubator contained 10 ml of Krebs-Henseleit buffer containing either vehicle (deionized H 2 O) or gAD (2-12 mg ml À1 in pilot study; 2 mg ml À1 was selected as the optimal dose) at 37 1C. After 2 h of incubation, the aortic rings were removed and immediately placed in organ chambers. The vasorelaxation studies and biochemical assays were performed as described below.
Determination of endothelial dependent and non-dependent vasodilation Endothelial function was determined by comparing the vasorelaxation response to Ach, an endothelium-dependent vasodilator, with that of SNP, an endothelium-independent vasodilator. Briefly, The aortic rings were suspended isometrically between two stainless steel hooks in organ chambers containing Krebs solution at 37 1C, and the top hook was connected to a force-displacement transducer connected to an amplifier and a data acquisition system (Power Lab; AD Instruments Ltd, Castle Hill, New South Wales, Australia), for continuous recording of isometric tension. After equilibration for 60 min at a preload of 1 g, the rings were precontracted with NE (1 mM). Once stable contraction was achieved, the rings were exposed to cumulative concentrations of Ach (10 -8 to 10 -4 M). In some experiments, the inhibitor of NO synthase L-NAME (0.5 mM) was added to the bath before NE administration. Relaxation values were expressed as percentage decreases in NE-induced vasoconstriction. After the cumulative response stabilized, the rings were washed and allowed to equilibrate to baseline. The procedure was then repeated with an endothelium independent vasodilator (SNP, 10 -8 to 10 -4 M) to determine smoothmuscle function and sensitivity to NO. Endothelial dysfunction was defined as reduced vasorelaxation in response to Ach, with normal response to SNP.
Total NO production measurement Total NO production (NOx) by aortic segments (3 mm) was determined by measuring the concentration of nitrite and nitrate with high-performance liquid chromatography system (included SHIMADZU System Controller SCL-10Avp, SHIMADZU Column Oven CTO-10Avp and SHIMADZU Liquid Chromatograph LC-10ATvp) by using Machery-Nagal Nucleosil 100-5 SB anion-exchange column. Samples were prepared as described by Everett et al. 14 Briefly, 100 ml of buffer solution were taken from the vascular chamber at cumulative Ach concentration of 10 À5 mM and subsequently 100 ml of acetonitrile were added, and then the sample mixed and centrifuged. A 50-ml volume of sample was injected into the high-performance liquid chromatography system. The eluant was 0.15 M (NH 4 ) 2 HPO 4 (pH 5.2); flow rate was 1.0 ml min À1 . Nitrite and nitrate were detected by the SHIMADZU SPD-10Avp UV-Vis detector at 214 nm. The nitrite/nitrate concentrations in the samples were calculated from freshly prepared nitrite/nitrate standard curves generated from sodium nitrite with the same Krebs buffer.
Cell culture
Human umbilical vein endothelial cells (HUVECs) were cultured using Dulbecco's Modified Eagle's Medium of low glucose with 10% N-Bromosuccinimide (NBS), 100 U ml À1 penicillin-G sodium, 100 mg ml À1 streptomycin sulfate, at 37 1C and under 5% CO 2 . Cells were seeded at 7 Â 10 5 per well in 2 ml Dulbecco's Modified Eagle's Medium in a sixwell dish with a piece of glass. In all experiments, HUVECs were serum-starved for 12 h before adding the stimulators. The levels of phosphorylation of endothelial nitric oxide synthase (eNOS), AMP-activated protein kinase (AMPK) and Akt were determined by immunocytochemistry. The images were analyzed by Image-pro plus and the level of phosphorylation was expressed as integrated optical density (IOD).
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Determination of the level of phosphorylation of eNOS at Ser1177
Cells were incubated for 15 min in medium containing 4 mg ml À1 recombinant human globular adiponectin. After incubation cells were washed with phosphate-buffered saline, fixed with 4% polyoxymethylene and the level phosphorylation of eNOS at Ser1177 was determined using anti-phospho-eNOS antibody (Ser1177) (1:200).
Determination of the level of phosphorylation of AMPK at Thr176 and Akt at Ser473
After incubation with 4 mg ml À1 recombinant human globular adiponectin for 15 min, phosphorylation of AMPK at Thr176 and Akt at Ser473 was detected using anti-phospho-AMPK (Thr172) (1:200)and anti-phospho-Akt (Ser473) (1:200) antibody.
Detection of the influence of AMPK inhibitor on increased activity of eNOS by adiponectin
To demonstrate that enhancement of eNOS activity was the result of increased phosphorylation of AMPK at Thr176, cells were preincubated with the AMPK inhibitor Compound C (20 mmol l
À1
) for 2 h. Subsequently, phosphorylation of eNOS at Ser1177 was detected with anti-phospho-eNOS (Ser1177) (1:200) after incubation with 4 mg ml À1 recombinant human globular adiponectin for 15 min.
Statistical analysis
Values are means ± s.d. Statistical analysis was performed by analysis of variance to detect significant differences in multiple comparisons. An unpaired Student's t-test was used to detect significant differences when two groups were compared. Differences with a P-value of 0.05 were considered statistically significant.
Result
Effect of high-fat diet on body weight and adiposity The final body weight (6 weeks) of the rats in the obese group was 30% more than the values for the control group (Table 1) . The mean visceral fat weight (W VF ) of obese group was nearly three times more than that of the control group. The ratio of the weight of visceral fat and body weight (W VF /BW) for obese rats was significantly higher than that of the control group (8.1 vs 3.1%, Po0.05).
Effect of globular adiponectin on endothelium-dependent and endothelium-independent vasodilation in obese rats The contraction amplitude of aortic rings pre-constricted with 1 mmol l À1 NE did not differ between the obese and control groups (2.06 ± 0.18 g for obese and 1.98 ± 0.14 g for control, P40.05). As indicated in Figure 1a , Ach percentage of maximal NE-induced vasoconstriction. Ach-induced vasorelaxation significantly reduced in obese rats in comparison with that in the control group (Po0.05). Globular adiponectin partially ameliorated impaired endothelium-dependent vasorelaxation in obese rat aortic rings, and the effect was eliminated by L-NAME, whereas endothelium-independent vasodilation remained unaffected. Data are expressed as mean±s.e. for each group (n ¼ 6-8 aortas). *Po0.05 obese rat rings vs control rat rings; } Po0.05 gAD-treated control rat rings vs vehicle-treated control rat rings; # Po0.05 gAD-treated obese rat rings vs vehicle-treated obese rat rings and y Po0.05 L-NAME þ gAD-treated obese rat rings vs gAD-treated obese rat rings alone. Ach, acetylcholine; gAD, adiponectin conserved globular domain; L-NAME, nitro-L-arginine methyl ester; NE, norepinephrine; SNP, sodium nitroprusside.
Adiponectin in endothelial dysfunction in obese rats G Deng et al in the OB group was impaired (82.3±5.6% vs 31.4±6.4%, Po0.01). Exposure of obese animal ring segments to gAD (2 mg; 120 min) increased Ach-induced vasodilation, the maximum Ach-induced vascular relaxation being 47.1 ± 8.9% (Po0.05). Preincubation with gAD had no significant effect on the maximum Ach-induced relaxation of control animal rings (85.6±4.6%, P40.05), but ring vasodilation was slightly increased at lower Ach concentration. Treatment of aortic rings for 15 min with 0.5 mmol l À1 L-NAME, an eNOS inhibitor, significantly eliminated the positive effect of gAD on impaired endothelium-dependent vasorelaxation in obese rats; in this group the maximum Ach-induced vascular relaxation was just 13.3%. This indicated enhanced eNOS activation may play a pivotal role in the effect of gAD on improving endothelium-dependent vasorelaxation in obese rats. As shown in Figure 1b , there was no significant difference of SNP-induced vasorelaxation between obese rats and control animals, with vasorelaxation of 99.5 and 99.8%, respectively. Concentration-response curves to SNP were not affected by pretreatment with adiponectin.
Effect of adiponectin on the total production of NOx
To obtain direct evidence that treatment with gAD may increase NO production, we measured total production of NOx by aortic segments isolated from control animals (NC) and obese animals treated with the vehicle, gAD (2 mg ml À1 ,120 min) alone or gAD with L-NAME. As shown in Figure 2 , production of NOx was significantly decreased in the obese group when compared with the control group (6.4 ± 0.8 mmol l À1 vs 15.3 ± 1.1 mmol l
À1
, Po0.05). Treatment with gAD increased the NOx production (10.5±1.1 mmol l À1 , Po0.05), which decreased to the baseline (5.22 ± 0.8 mmol l
) in the presence of the eNOS-specific inhibitor L-NAME.
The AMPK-eNOS signal pathway is critical in the improvement of globular adiponectin on endothelial dysfunction Effect of globular adiponectin on phosphorylation of eNOS at Ser1177. The (Figure 3 Effect of globular adiponectin on phosphorylation of AMPK at Thr176 and Akt at Ser473. As indicated in Figures 4a and b , it was AMPK but not Akt that was involved in the activation of eNOS by gAD. gAD caused obvious AMPK (Thr172) phosphorylation with almost three times IOD of the control group (Po0.01), whereas Akt (Ser473) phosphorylation in the gAD group was level with that in the control group (IOD ¼ 10671.24 vs 10869.7, P40.05).
The influence of AMPK inhibitor on increased activity of eNOS by adiponectin. The conserved globular domain could not stimulate the phosphorylation of eNOS at Ser1177 in HUVECs in the presence of AMPK inhibitor Compound C (Figure 4c ). The level of eNOS (Ser1177) phosphorylation Figure 2 Total NO production (NOx) by aortic segments isolated from control animals (NC) or obese animals treated with the vehicle (OB), gAd (2 mg ml À1 , 120 min) alone (OB þ gAd) and gAd (2 mg ml
) with L-NAME (OB þ gAd þ L-NAME). Total production of NOx was significantly decreased in the obese group as compared with that in the control group. Globular adiponectin treatment increased NOx production, which was abolished by L-NAME. Data are expressed as mean±s.e. for each group (n ¼ 6-8 aortas). *Po0.05 vs control rat aortic segments; # Po0.05 vs vehicle-treated obese rat aortic segments and y Po 0.05 vs gAD-treated obese rat aortic segments. Ach, acetylcholine; gAD, adiponectin conserved globular domain; L-NAME, nitro-Larginine methyl ester; NE, norepinephrine; NO, nitric oxide; NOx, total nitric oxide production; SNP, sodium nitroprusside. 
Discussion
In this study, we provided direct evidence showing that diminished ability of endothelium-dependent vasodilation in high-fat-diet-induced obese rats was partly restored by gAd. The endothelium is a major paracrine organ that plays critical roles in controlling vascular tone, inflammation and smooth-muscle-cell proliferation. Endothelial dysfunction characterized by deficiency of NO production in response to normal secretion signals, is a characteristic abnormality observed in obesity-associated metabolic syndrome, and is a critical component of atherosclerosis development. 15 Recently, a growing body of evidence showed that hypoadiponectinemia is associated with endothelial dysfunction. Ouchi et al. 16 found that hypoadiponectinemia is associated with impaired endothelium-dependent vasorelaxation. These results were confirmed through animal studies by showing that adiponectin-deficient mice display impaired endothelium-dependent vasodilation and NO production. 17 Ohashi et al. 18 showed that adiponectin-knockout mice had decreased nitrate/nitrite levels as compared with wild-type littermates after high-salt feeding. In the current study, we have demonstrated that gAd ameliorated impaired endothelium-dependent vasodilation of thoracic aorta in high-fat-diet-induced obese rats in vitro, with the Achinduced vascular relaxation increasing from 31.4 ± 6.4 to 47.1 ± 8.9%; and there was no change in SNP-induced, endothelium-independent vasorelaxation. Since these favorable effects were observed on aortic rings incubated with gAD in organ bath, this action of gAD appears to be largely independent of improved peripheral insulin sensitivity. Impaired endothelial vasodilation in obese rats arose from decreased production and/or bioactivity of NO. In the present study, we identified that gAD significantly enhanced total production of NO from thoracic aoritic rings as compared with that from artery rings from obese rats without gAD preincubation (Po0.05); this beneficial effect disappeared when the eNOS-specific inhibitor L-NAME was added. Similarly, the ameliorating effect of gAD on endothelium-dependent vasodilation was also blocked by L-NAME. The message delivered from the cultured HUVECs in vitro was that eNOS could be activated by gAD through phosphorylated serine at position 1177. Altogether, our results are consistent with the present understanding that the gADprotective effect on endothelium was mediated by eNOS. Previous studies have demonstrated that adiponectin exerts its beneficial effects through membrane-bound receptors and adaptor molecules in endothelial cells. Adiponectin increases the stability of eNOS mRNA and half-life, enhances the association of eNOS with Hsp90 and stimulates the phosphorylation of eNOS, which together lead to increased NO production. 19, 20, 21 Our result provided direct evidence supporting the notion that elevating plasma adiponectin levels increase NO production and vasodilation, and protect against endothelial dysfunction and subsequent cardiovascular disease.
Oxidative stress has long been recognized to act as one of the major mediators of endothelial dysfunction and increased oxidative stress diminishes the bioavailability of NO. Some studies demonstrate that treatment with gAd Adiponectin in endothelial dysfunction in obese rats G Deng et al significantly inhibited basal superoxide release by bovine aortic endothelial cells, and abolished the oxidized, low-density lipoprotein-induced increase in superoxide production. 22 It is also found that adiponectin may blocked high-glucose-induced endothelial superoxide production in vascular endothelial cells, which indicates that the superoxide suppression effect of adiponectin is a general property of this novel molecule. 23 The animal study showed that bioactive NO was markedly reduced in aortic rings isolated from adiponectin-knockout mice. Moreover, in vitro acute incubation of aortic vascular rings from adiponectin-knockout animals with Tiron, a superoxide scavenger, significantly improved vascular vasodilatory response to ACh. 24 So it is logical to deduce that the beneficial actions of adiponectin to improve the endothelium-dependent vasodilation observed in this study might also be associated with decreasing NO inactivation by blocking superoxide production. The cellular mechanisms by which adiponectin stimulate the phosphorylation of eNOS remain to be defined. Growing evidence suggests that AMPK, a central regulator of cellular energy metabolism, plays a key role in modulating vascular reactivity. AMPK stimulates eNOS activity by phosphorylating eNOS at Ser1177. Several vasoprotective agents, such as the antidiabetic drug metformin, had been shown to activate AMPK in endothelial cells. 25 Consistent with the previously reported findings, 19, 26 our results demonstrated that gAD significantly enhanced the level of AMPK (Thr172) phosphorylation, which suggests that AMPK is the principal kinase responsible for adiponectin-evoked eNOS phosphorylation in HUVECs. This notion is supported by our finding that gAd-induced eNOS (Ser1177) phosphorylation was abrogated by AMPK inhibitor. Recent studies have found that selective PI3-kinase inhibitors could abrogate adiponectin-evoked phosphorylation of AMPK at Thr172 and of eNOS at Ser1177, and NO production in endothelial cells, 27, 28 suggesting that activation of AMPK/eNOS by adiponectin is mediated by PI3-kinase. In insulin signaling pathways in endothelium, Akt is downstream from PI3-kinase and is capable of directly phosphorylating eNOS at Ser1179, resulting in its activation. 29 Whether adiponectin-induced AMPK-eNOS activation is mediated by Akt phosphorylation is controversial.
Results from the present study did not find adiponectioninduced Akt (Ser473) phosphorylation, which was consistent with the report that globular adiponectin could not enhance the Ser473 phosphorylation of Akt in adipocytes. 30 We speculate that although phosphorylation of eNOS on Thr1177 was PI3-kinase-dependent, it was independent of Akt activation. In summary, determining the mechanism of regulation of endothelial function by adiponectin may provide insight into its salutary role in the pathogenesis of the vascular complications of obesity/metabolic syndrome. The demonstration in the current study that adiponectin reverses endothelial dysfunction through increasing NO production by eNOS phosphorylation and decreasing NO inactivation by blocking superoxide production, provides a new direction in the prevention of vascular injury in the obesity population. The molecular pathways appear to involve increased AMPK but not Akt activity. The fact that insulin and adiponectin regulate activation of eNOS by slightly different mechanisms suggests that therapies designed to increase adiponectin levels may be beneficial in the treatment of obesity/metabolic syndrome, and its vascular complications.
